

Sox9 determines translational capacity during early chondrogenic differentiation of ATDC5 cells by regulating expression of ribosome biogenesis factors and ribosomal proteins

Marjolein M.J. Caron^{1†*}, Maxime Eveque^{2†}, Berta Cillero-Pastor², Ron M. A. Heeren², Bas Housmans¹, Kasper Derks³, Andy Cremers¹, Mandy J. Peffers⁴, Lodewijk W. van Rhijn¹, Guus van den Akker^{1†}, Tim J.M. Welting^{1†}

¹Laboratory for Experimental Orthopedics, Department of Orthopedic Surgery, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Center. P.O. Box 5800, 6202 AZ, Maastricht, the Netherlands.

²Maastricht MultiModal Molecular Imaging institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University Medical Center. P.O. Box 5800, 6202 AZ, Maastricht, the Netherlands.

³Department of Clinical Genetics, Maastricht University Medical Center. P.O. Box 5800, 6202 AZ, Maastricht, the Netherlands.

⁴Department of Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom

† contributed equally

* Correspondence:

Marjolein M.J. Caron, PhD

e-mail: marjolein.caron@maastrichtuniversity.nl

Keywords: ATDC5, chondrogenesis, Sox9, ribosome, translation, proteomics, transcriptomics

30 **Abstract**

31 Introduction: In addition to the well-known cartilage extracellular matrix-related expression of Sox9,
32 we demonstrated that chondrogenic differentiation of progenitor cells is driven by a sharply defined
33 bi-phasic expression of Sox9: an immediate early and a late (extracellular matrix associated) phase
34 expression. In this study we aimed to determine what biological processes are driven by Sox9 during
35 this early phase of chondrogenic differentiation.

36 Materials: Sox9 expression in ATDC5 cells was knocked-down by siRNA transfection at the day
37 before chondrogenic differentiation or at day 6 of differentiation. Samples were harvested at 2 hours,
38 and 7 days of differentiation. The transcriptomes (RNA-seq approach) and proteomes (Label-free
39 proteomics approach) were compared using pathway and network analyses. Total protein translational
40 capacity was evaluated with the SuNSET assay, active ribosomes with polysome profiling and
41 ribosome modus with bicistronic reporter assays.

42 Results: Early Sox9 knockdown severely inhibited chondrogenic differentiation weeks later. Sox9
43 expression during the immediate early phase of ATDC5 chondrogenic differentiation regulated the
44 expression of ribosome biogenesis factors and ribosomal protein subunits. This was accompanied by
45 decreased translational capacity following Sox9 knockdown, and this correlated to lower amounts of
46 active mono- and polysomes. Moreover, cap- versus IRES-mediated translation was altered by Sox9
47 knockdown. Sox9 overexpression was able to induce reciprocal effects to the Sox9 knockdown.

48 Conclusion: Here we identified an essential new function for Sox9 during early chondrogenic
49 differentiation. A role for Sox9 in regulation of ribosome amount, activity and/or composition may be
50 crucial in preparation for the demanding proliferative phase and subsequent cartilage extracellular
51 matrix-production of chondroprogenitors in the growth plate *in vivo*.

52 Introduction

53 Chondrogenesis, or chondrogenic differentiation, is the differentiation path of progenitor cells via early
 54 mesenchymal condensation into chondrocytes that synthesize a cartilaginous extracellular matrix
 55 (ECM) (1-3). Aside from formation of articular cartilage and its maintenance, skeletal development
 56 also depends on chondrogenic differentiation. Development of the long bones of the mammalian
 57 skeleton depends on the activity of growth plates; cartilaginous entities at the ends of developing bones
 58 in which chondrocytes differentiate from progenitor cells (1-3). In contrast to articular chondrocytes,
 59 differentiating growth plate chondrocytes are predestined to undergo hypertrophic differentiation and
 60 apoptosis. The remaining cartilaginous matrix is subsequently remodelled by osteoclastic/osteocytic
 61 activity, resulting in *de novo* synthesized bone tissue (1-3). *In vivo*, chondrogenic differentiation is
 62 almost exclusively initiated from local mesenchymal progenitor cells that reside in the cartilaginous
 63 tissue (growth plate resting zone (4), articular cartilage superficial layer(5)) or in surrounding fibrous
 64 tissues (e.g. periosteum (6, 7)). However, *in vitro* chondrogenic differentiation has been reported from
 65 various primary (mesenchymal) progenitor cell sources including synovial membrane/fluid, bone
 66 marrow, adipose tissue, fibroblasts, and induced pluripotent stem cells (8-10). In addition to high
 67 amounts of oligosaccharides (mostly hyaluronic acid, heparan sulphate, chondroitin sulfate), important
 68 cartilage ECM proteins are type II collagen (Col2a1) and aggrecan (Acan)(2, 11, 12).

69 The master regulator of chondrogenic differentiation is the transcription factor SRY (sex determining
 70 region Y)-box 9 (Sox9). Mutations in *SOX9* were originally identified as the cause for campomelic
 71 dysplasia (13, 14), a severe skeletal dysplasia associated with XY sex reversal and disproportionally
 72 short stature, as well as general lack of cartilaginous tissue formation. *SOX9* was found to be essential
 73 for murine early chondrogenic lineage determination (15). Upon nuclear translocation (16, 17), Sox9
 74 binds as a homodimer to its consensus DNA recognition sequence (A/T)(A/T)CAA(A/T)G(18), which
 75 includes the highly conserved AACAAAT motif recognized by the HMG-box domain shared amongst

76 Sox and Sry protein family members. In chondrogenic differentiation Sox9 drives the transcription of,
 77 and cooperates with L-Sox5 and Sox6 for efficient transcription of the *COL2A1* and *ACAN* genes (15,
 78 19-22). Other cartilage ECM genes have also been demonstrated as under transcriptional control of
 79 SOX9; including *COL9A1* (23), *COL27A1* (24), and *MATN1* (25, 26). Besides L-Sox5 and Sox6,
 80 another important factor for Sox9-mediated transcription is Smad3. Smad3 modulates the interaction
 81 between Sox9 and CBP (CREB-binding protein)/p300 (27), thereby possibly explaining the pro-
 82 chondrogenic effect of bone morphogenetic proteins (BMPs) and transforming growth factor beta
 83 (TGFβs) on chondrogenic differentiation (28, 29).

84 During chondrogenic differentiation of progenitor cells *in vitro*, induction of Sox9 expression is
 85 biphasic (30). In the first hours after initiation of chondrogenic differentiation Sox9 expression is
 86 transiently induced (immediate early Sox9 induction), together with the other members of the “Sox-
 87 trio”. Sox9 expression increases a second time, in parallel with the synthesis of cartilage ECM
 88 molecules (late Sox9 induction). Previously, we demonstrated that this immediate early Sox9
 89 expression is in part regulated by the immediate early response gene 1 (Egr1) (31) as well as by
 90 NFκB/p65 (30). Similar expression patterns were also found in growth plate sections (30). The function
 91 of the early Sox9 induction itself remains elusive. In the present work we therefore determined the
 92 transcriptomic and proteomic consequences of the abrogation of early Sox9 expression during ATDC5
 93 chondrogenic differentiation, and uncovered the biological processes that are driven by Sox9 during
 94 the early phase of chondrogenic differentiation.

95 **Materials and methods**

96

97 ATDC5 cell culture

98 ATDC5 cells (RIKEN BRC, Japan, STR profiled)(32) were cultured in a humidified atmosphere at
99 37°C and 5% CO₂ in culture media consisting of Dulbecco's Modified Eagle Medium (DMEM)/F12
100 (Life Technologies, Waltham, Massachusetts, USA), 5% fetal calf serum (Life Technologies), 1%
101 antibiotic/antimycotic (Life Technologies) and 1% non-essential amino acids (NEAA)(Life
102 Technologies). Chondrogenic differentiation was induced by plating the cells in triplicates at 6400
103 cells/cm², or 20,000 cells/cm² in transfection experiments, and the addition to culture media of
104 differentiation supplements 10 µg/ml insulin (Sigma-Aldrich, St. Louis, Missouri, United States), 10
105 µg/ml transferrin (Roche, Basel, Switzerland), and 30 nM sodium selenite (Sigma-Aldrich). Media
106 was refreshed every two days.

107

108 Sox9 loss and gain of function

109 A small interfering RNA (siRNA) duplex for Sox9 ("Sox9 RNAi") (sense: 5'-
110 GACUCACAUCUCUCCUAAUTT-3', anti-sense: 5'-AUUAGGAGAGAUGUGAGUCTT-3') and a
111 scrambled siRNA duplex ("Control RNAi", Eurogentec, Seraing, Belgium) were transfected (100 nM)
112 one day prior to initiation of chondrogenic differentiation or at day 6 of differentiation using
113 HiPerFECT according to manufacturers' protocol (Qiagen, Hilden, Germany). A custom made DNA
114 strand containing a start codon and 3xFLAG sequence (derived from p3xFLAG CMV7.1) and the
115 mSox9 coding sequence (NM_011448.4:376-1899) without start codon was flanked by 5'EcoRI and
116 3'XbaI restriction sites (GeneCust, Boynes, France). This fragment was cloned directionally into the

117 pLVX-EIF1 α -IRES puro MCS (Takara, Saint-Germain-en-Laye, France) to generate a pLVX-EIF1 α -
118 mSox9-IRES puro transfer plasmid. Lentiviral particles were generated according to manufacturer's
119 instructions with the 4th generation VSV-G envelope Lenti-X system (Takara, Saint-Germain-en-Laye,
120 France). Lentiviral titers were determined by p24 ELISA (enzyme-linked immunosorbent assay;
121 INNOTEST HIV antigen mAb, Fujirebio, Zwijnaarde, Belgium). Viral transductions were performed
122 by incubation of 1 ng lentivirus/cell in the presence of 8 μ g/mL polybrene (Sigma-Aldrich) for 8 hours,
123 followed by an overnight incubation with 1.6 μ g/mL polybrene.

124

125 RNA isolation

126 RNA was isolated using TRIzol (Life Technologies), collecting the aqueous phase after centrifugation.
127 RNA was precipitated with isopropanol (VWR International, Radnor, Pennsylvania, USA) (-80°C) and
128 pellet by centrifugation. RNA pellets were washed in 80% ethanol (VWR International) and dried.
129 RNA was dissolved in DNase/RNase-free pure water. RNA quantity and purity were determined
130 spectrophotometrically (Biodrop, Isogen Life Sciences, Utrecht, The Netherlands).

131

132 Quantitative real time PCR

133 Total RNA was reverse transcribed into cDNA using standard procedures and random hexamer
134 priming as previously described (33). Real-time quantitative PCR (RT-qPCR) was performed using
135 Mesagreen qPCR master mix plus for SYBR Green (Eurogentec, Liège, Belgium). A CFX96 Real-
136 Time PCR Detection System (Biorad, Hercules, California, United States) was used for amplification:
137 initial denaturation 95°C for 10 minutes, followed by 40 cycles of amplification (denaturing 15 seconds
138 at 95°C and annealing 1 minute at 60°C). Validated primer sequences are shown in Supplemental Table

1. Data were analyzed using the standard curve method, mRNA expression was normalized to a reference gene and gene expression was calculated as fold change as compared to control conditions or $t=0$.

RNA-sequencing and analysis

Isolated RNA was checked for quality and integrity on the Agilent 2100 Bioanalyzer (Santa Clara, California, USA) via 2100 an Expert Eukaryote Total RNA Nano chip according manufacturer's protocol. The mRNA sequencing library was generated using TruSeq mRNA sample preparation kit (Illumina, Eindhoven, the Netherlands). In short, mRNA was enriched using magnetic beads coated with poly-dT, followed by fragmentation. The fragmented mRNA enriched samples were subjected to cDNA synthesis by reverse transcriptase, followed by dA-tailing and ligation of specific double-stranded bar-coded adapters. Next, the library was amplified and following cleanup the sizes of the libraries were determined on an Agilent 2100 Bioanalyzer via a DNA 1000 chip according manufacturer's protocol. Pooled libraries consisting of equal molar samples were sequenced on a high-output 75bp single read on the NextSeq500 (Illumina). For each sample, the number of reads covering one or more exons of a given transcript were extracted. Triplicates of samples that were treated with either Scrambled or Sox9 siRNAs, at two different time points, were grouped separately. A transcript was defined as expressed when all replicates of a group had at least 5 reads extracted within the transcript's region. The grouped data were then compared to one another. The fold-change difference and the p-value were calculated using R-package edgeR (34, 35), after which the p-value was corrected for multiple testing (false discovery rate (FDR)-corrected). Transcripts having an FDR-corrected p-value <0.05 , and a fold change of at least 1.5 were considered differentially expressed transcripts. RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-10333. EnrichR (36) software was used to display the pathways of interest obtained from the enrichment of down or up-regulated proteins.

The top three pathways of interest were considered from both Wikipathways and KEGG software (version 2019, Mouse) based on the combined score of the p-value and the adjusted p-value scores.

Label-free proteomics

At indicated time points, plates were rinsed 3 times with 1% phosphate buffered saline (PBS). A mixture containing complete Mini Protease Inhibitor Cocktail (Roche, Basel, Switzerland) in 25 mM ammonium bicarbonate (ABC) buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 6M urea (GE Healthcare, Eindhoven, The Netherlands) was added to the plates. Cells were collected by scraping with a rubber policeman and the samples were transferred to Eppendorf tubes. Triplicates were pooled and sonicated for 10 minutes and centrifuged at 12.000g for 10 min in 4°C. The supernatant containing proteins was transferred into new tubes and a Bradford assay (Biorad, Lunteren, the Netherlands) was performed to assess protein concentration. The concentrations were adjusted to 0.2µg/µL in order to normalize for the following steps. Samples were reduced with 20mM of Dithiothreitol (DTT) (Sigma-Aldrich) for 45 minutes and alkylated with 40 mM of iodoacetamide (IAM; Sigma-Aldrich) for 45 minutes in the dark. The alkylation step was stopped by adding 20 mM of DTT. Samples were then digested using LysC and trypsin (Promega, Leiden, The Netherlands) added at a ratio of 1:25 (enzyme:protein) and incubated for 2 hours at 37°C in a water bath. Finally, 200 µL of 25 mM ABC buffer was added to the samples before overnight incubation at 37°C. The digestion was stopped by adding formic acid (FA; Sigma-Aldrich) and acetonitrile (Biosolve) at a final concentration of 1% and 2%, respectively. 200 ng of each sample were injected in duplicate for liquid-chromatography mass spectrometry (LC-MSMS) analysis. The separation of the peptides was performed on a Thermo Fisher Scientific Dionex Ultimate 3000 Rapid Separation ultrahigh-performance liquid-chromatography (HPLC) system (Thermo Scientific, MA, USA) equipped with an Acclaim PepMap C18 analytical column (2µm, 75µm*150 mm, 100Å). The samples were first trapped on an online C18 column for desalting. The peptides were then separated on the analytical column with a 90-minutes linear gradient

from 5% to 35% acetonitrile/0.1% FA and a flow rate set at 300 nL/min. The HPLC system was coupled to a high mass resolution Orbitrap MS instrument (Q-Exactive HF, Thermo Scientific, Waltham, MA). The mass spectrometer was operated in data-dependent acquisition (DDA) mode with the following settings: Full MS scan of the mass range m/z 350-1,650 at a resolution of 120,000 at m/z 400, followed by tandem mass spectrometry (MS/MS) scans for the fragmentation of the 15 most intense ions at a resolution of 30,000. The ions already selected for fragmentation were dynamically excluded for 20s. External calibration of the instrument was performed using a standard calibration solution for positive ion mode (Thermo Scientific). For protein identification, raw files were processed within the Proteome Discoverer software version 2.2 (Thermo Scientific) using the search engine Sequest with the Swiss-Prot database *Mus musculus* version 2017-10-25 (TaxID 10090). The following parameters were used for the database search: carbamidomethylation of Cysteine for fixed modifications; oxidation of Methionine and acetylation of protein N-terminal for variable modifications; trypsin for enzyme with a maximum of two missed cleavages; y and b for the ion types with a mass tolerance of 10 ppm and 0.02 Da for the precursors and the fragments, respectively; minimum and maximum peptide length of 6 and 144, respectively. Normalization of the data was performed on the total peptide amount. Percolator was used for the decoy database search and the FDR was fixed at 1% maximum. Finally, a list of 23 commonly detected contaminants were removed manually (data not shown). For protein quantitation, the Minora Feature Detector node in the processing step and the Feature Mapper node combined with the Precursor Ions Quantifier node in the consensus step were used with default settings. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (37) partner repository with the dataset identifier PXD024715. ANOVA test and principal component analysis (PCA) were performed within the Proteome Discoverer software. PCA was performed to visualize protein abundance changes between groups in an unsupervised manner. ANOVA test was used to analyze the statistical significance of variation observed in protein abundances between the conditions. The proteins were

considered modulated with a p-value ≤ 0.05 and a fold change (FC) ≥ 2 . The modulated proteins were then imported within the EnrichR software (36) to display the top 3 pathways of down or up-regulated proteins ranked by the combined score. WikiPathways and KEGG were used as databases (version 2019, Mouse).

Immunoblotting

Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0,5% Sodium deoxycholate, 0,1% SDS, 50 mM Tris pH 8.0, 5.0 mM Ethylenediaminetetraacetic acid (EDTA) pH 8.0, 0.5 mM dithiothreitol (DTT) supplemented with cOmplete Mini Protease Inhibitor Cocktail (Roche) and PhosSTOP phosphatase inhibitor (Sigma-Aldrich)). Extracts were sonicated and protein concentrations were determined with a bicinchoninic acid assay (BCA) assay (Sigma-Aldrich). Proteins were separated by SDS-PAGE (sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis) and transferred to nitrocellulose membranes by electroblotting. Primary antibodies for immunodetection were anti-Sox9 (Abcam, Cambridge, UK; ab3697) and anti-Tubulin (Sigma-Aldrich; T6074). Bound primary antibodies were detected using immunoglobulins conjugated with HRP (horseradish peroxidase; DakoCytomation, Glostrup, Denmark) and visualized by enhanced chemoluminescence (ECL). ECL signals were quantified using Image J 1.46f software (Figure 1B). Relative differences in Sox9 levels, corrected for background and Tubulin levels, were determined as compared to t=0 conditions.

sGAG assay

The sulphated glycosaminoglycan (GAG) content was measured using a modified dimethyl methylene blue (DMB) assay (38). The absorbance of samples was read at 540 and 595 nm using a spectrophotometer (Multiskan FC, Life Technologies) and GAG concentrations were calculated using

a chondroitin sulfate standard curve (Sigma-Aldrich) and corrected for total protein content using a BCA assay.

SUnSET assay

Protein translational capacity of ATDC5 cultures (in sextuplicates) was assessed with the SUnSET assay (39, 40). 5.4 μ M puromycin (Sigma-Aldrich) was incubated for 15 minutes in the cell culture medium, immediately followed by washing in PBS and fixation for 20 minutes with 10% formalin (VWR, Radnor, Pennsylvania, United States). Permeabilization was performed for 10 minutes with PBS supplemented with 0.1% Triton X-100. Wells were rinsed with PBS with 0.1% Tween (PBS-T) and blocked for 1.5 hour with 1% (m/v) skimmed milk powder (ELK, Campina, Zaltbommel, the Netherlands) in PBS-T, followed by overnight incubation at 4°C with the primary anti-puromycin antibody 12D10 (Sigma-Aldrich). After washing with PBS-T, wells were incubated for 1 hour at room temperature with the secondary goat anti-mouse Alexa488 antibody (Life Technologies). The fluorescent signal intensity was determined using a TriStar² LB942 (Berthold, Bad Wildbad, Germany) equipped with excitation filter F485 and emission filter F535. Fluorescent data was normalized to DNA-content from the same well (41). To this end, wells were washed with HEPES-Buffered Saline (HBS), followed by 1 hour incubation with 5 μ g/mL DAPI (Life Technologies) plus 5 μ g/mL HOECHST 33342 (Life Technologies) in HBS. After subsequent washing steps with HBS, fluorescent signal intensity was determined using a TriStar² LB942 (Berthold), using the excitation filter F355 and emission filter F460.

256 Polysome fractionation

257 Polysome fractionation was performed as described previously (42). Three 15 cm plates with ATDC5
 258 cells were used to generate a single sample. At the day of sample collection, cells were differentiated
 259 for 2 hours, then pre-treated for 5 minutes with 100 µg/ml Cycloheximide (Sigma), washed twice in
 260 0.9% NaCl with Cycloheximide and collected by scraping with a rubber policeman in cold 0.9% NaCl.
 261 Pelleted cells were lysed for 10 minutes in 1.8 ml polysome extraction buffer (20 mM Tris-HCl
 262 (pH7.5), 100 mM KCl, 5 mM MgCl₂, 0.5% Nonidet P-40, 100 µg/ml Cycloheximide, complete
 263 protease inhibitor cocktail (Roche) and RNasin (Promega, 40U/ml)) on ice. Nuclei and cellular debris
 264 were removed by centrifugation at 12.000x g for 10 minutes at 4⁰C and 9/10th of the total volume was
 265 transferred to fresh tubes and measured spectrophotometrically. Total yield was the same for siCtrl and
 266 siSox9 treated cells. Sucrose gradients (linear 10-50%) were made using the Gradient Master
 267 (BioComp) in ultracentrifuge tubes (Seton, SW41 tubes). Cytoplasmic extracts (250 µg/sample) were
 268 loaded to each gradient in a fixed volume (400 µl). Gradients were run on an ultra-centrifuge (Beckman
 269 L60, Brea, California, USA) at 39.000 rpm for 1.5 hours at 4⁰C with max acceleration and deceleration
 270 9. Samples were fractionated into 24 x 0.5 ml fractions using a Piston Gradient fractionator (BioComp,
 271 Fredericton, Canada) and fraction collector (Gilson FC203B, Middleton, Wisconsin, USA) with
 272 continuous A260 monitoring (Triax FC-1).

273

274 Bicistronic reporter assay

275 Reporter constructs for the CrPv IGR IRES, the CrPv CCGG IGR IRES mutant, the HCV and the P53
 276 IRES were a kind gift of Dr. S. Thompson (UAB, USA). One day post plating, maxi-prep DNA (0.5
 277 µg/well) and 100 nM siRNA were transfected into 24-wells wells (n=3/group) using Mirus Transit-X2
 278 according to manufacturer's instructions. The next day differentiation was induced for 24 hours,

279 samples were collected by washing cells with 0.9% NaCl and incubation in 100 µl passive lysis buffer
280 for 15 minutes (Promega). Subsequently, samples were transferred to Eppendorf tubes and centrifuged
281 for 10 minutes at 12.000x g in a tabletop centrifuge. Next, 50 µl lysate was used for dual luciferase
282 measurements (Promega) using a Berthold injection system (Reeuwijk, the Netherlands; 10 seconds
283 counting time per cistron). Data is represented as fold change of the ratio Fluc/Rluc in control cells for
284 each IRES.

285 Statistics in other than proteomics or transcriptomic analysis

286 Statistical significance was determined by two-tailed student t-tests using Graphpad PRISM 5.0 (La
287 Jolla, CA, USA). Error bars in graphs represent mean \pm standard error of the mean. Significance for
288 all tests was set at $p \leq 0.05$.

Results

Early Sox9 peak in ATDC5 chondrogenic differentiation

Induction of Sox9 expression is biphasic during chondrogenic differentiation of progenitor cells *in vitro* (30, 31). In the first (2-4) hours after initiation of chondrogenic differentiation of ATDC5 cells Sox9 expression was transiently induced on mRNA (Figure 1A) and protein level (Figure 1B). Sox9 expression increased a second time around day 7 in differentiation (Figure 1A), in parallel with the expression of the important Sox9 transcriptional target Col2a1 (21) (Figure 1C) and gain of sulphated glycosaminoglycan (GAG) content (2, 19) (Figure 1D). The immediate early transient Sox9 expression peak at 2 hours in differentiation did not correlate with the induction of expression of well-known Sox9 transcriptional targets such as Col2a1. Hence, we questioned what the function of the early Sox9 expression peak (2 hours) was and how it differs from the later Sox9 activity (day 7). We approached this by performing a loss-of-function experiment and comparing the Sox9-dependent transcriptome and proteome in an unbiased manner.

Transcriptome and proteome analysis at 2 hours and 7 days in ATDC5 chondrogenic differentiation under Sox9 knockdown

To target early Sox9 expression, a siRNA for Sox9 or scrambled control siRNA were transfected prior to initiation of differentiation (t = -1 day) (Figure 2A). At t=0 chondrogenic differentiation was induced and cells were differentiated for 14 days. We established effective knockdown of Sox9 at t=0 and t=2 hours in differentiation, while at day 5, 7 and 14 in differentiation Sox9 mRNA levels returned to scrambled siRNA control conditions (Figure 2B; black bars and Figure 2C). In parallel, ATDC5 cells were differentiated and the siRNA for Sox9 or scrambled siRNA was transfected at day 6 in differentiation, to specifically target expression of “late” Sox9 induction. Effective knockdown of Sox9

at day 7 and day 14 was observed at mRNA as well as (Figure 2B; grey bars) at the protein level (Figure 2C). Knockdown of the early Sox9 expression peak resulted in decreased Col2a1 expression, and increased Col10a1 expression at early time-points. At day 7 and 14 in ATDC5 differentiation, Sox9 siRNA treatment was not effective anymore (Figure 2B; white versus black bars), however, a major induction of Col2a1 mRNA expression at day 7 and 14 in differentiation was prevented in this condition (Figure 2D). A similar but opposite effect was seen for Col10a1 expression in the early Sox9 peak knockdown condition (Figure 2E). Knockdown of the “late” Sox9 peak (grey bars) also resulted in a decreased Col2a1 and increased Col10a1 expression at day 7 and 14 in differentiation, with a smaller magnitude. These data indicate that the early Sox9 expression peak is paramount for successful chondrogenic differentiation of ATDC5 cells (see Supplemental Figure 1 for confirmation with independent Sox9 siRNA). Differential expression of mRNAs and proteins was determined between the scrambled versus Sox9 siRNA at 2 hours as well as at 7 days in ATDC5 differentiation, to target the early and late Sox9 expression peaks (Figure 2D).

The extracted RNA was used for RNA sequencing and Principal Component Analysis (PCA) of the transcriptome confirmed that samples from the 4 groups separated (Supplementary Figure 2). Noteworthy, the separation between the scrambled siRNA and Sox9 siRNA conditions was evident at 2 hours, while separation between the scrambled siRNA and Sox9 siRNA conditions at 7 days was less clear. At 2 hours in ATDC5 chondrogenic differentiation, knockdown of Sox9 led to the differential expression of 2422 genes, with 1235 upregulated genes and 1187 downregulated genes (Figure 3A/B). At 7 days in differentiation 493 genes were differentially expressed (203 up and 290 down) due to knockdown of Sox9. From these differentially expressed genes, 203 genes were upregulated (only 15 overlapped with the 2 hour time point) and 290 genes were downregulated (49 genes overlapped with the 2 hours condition) (Figure 3A/B). All genes that were differentially expressed ($FC \geq 2$; $p < 0.05$) at 2

335 hours and at 7 days in ATDC5 chondrogenic differentiation following Sox9 knockdown, are shown in
336 Supplementary Tables 2 and 3, respectively.

337 Proteins from control conditions and Sox9 knockdown conditions at 2 hours and 7 days in ATDC5
338 differentiation were quantified using a label-free proteomics approach. PCA plotting confirmed that
339 control samples at 2 hours clearly separated from the Sox9 knockdown samples at 2 hours in ATDC5
340 differentiation. Separation between control and Sox9 knockdown conditions was also confirmed at 7
341 days in chondrogenic differentiation. However, and in concert with the PCA plot of the RNA
342 sequencing data (Supplementary Figure 2), the separation between control and Sox9 knockdown
343 conditions appeared to be most obvious at 2 hours in differentiation (Supplementary Figure 3A). At 2
344 hours in differentiation, knockdown of Sox9 caused the differential expression of 90 proteins (29 up
345 and 61 down)(Figure 3C/D and Supplemental Figure 3B). At 7 days in differentiation, the knockdown
346 of Sox9 induced differential expression of 19 proteins (9 up and 10 down). There was no overlap
347 between the Sox9-dependent differentially expressed proteins at 2 hours or at 7 days in differentiation
348 (Figure 3C/D and Supplemental Figure 3B). The proteins that were differentially expressed ($FC \geq 2$;
349 $p < 0.05$) at 2 hours and at 7 days in ATDC5 chondrogenic differentiation following Sox9 knockdown,
350 are shown in Supplementary Tables 4 and 5, respectively.

351 These data indicate that at 2 hours in chondrogenic differentiation the knockdown of Sox9 induced
352 different changes in the ATDC5 transcriptome and proteome when compared to knockdown of Sox9
353 at 7 days in differentiation. In addition, the consequences of Sox9 siRNA treatment appears to be
354 stronger at 2 hours than at 7 days of differentiation, as indicated by larger separation in the PCA plots
355 and larger number of differentially expressed genes and proteins. The role of the immediate early Sox9
356 expression was further investigated by comparing the Sox9-dependent differentially expressed mRNAs
357 and proteins at 2 hours in differentiation. Four overlapping mRNAs and proteins are upregulated in the
358 early Sox9 knockdown condition (Rps30/Fau, Avan, Eefsec, Rpl38; Figure 3E and 3F, Supplementary

Table 6) and 3 overlapping mRNAs and proteins downregulated in the early Sox9 knockdown condition (Ube2d3, Dcl1, Svl; Supplementary Table 6). Except for Rpl38, these overlapping targets are unique for the 2 hour in differentiation time point. The relative low number of overlapping genes and proteins (Figure 3E and F) might be explained by the different control of expression regulation at different levels for RNA and protein (43) and the notion that not all mRNAs are instantaneously translated into protein. Overlapping targets might be involved in a biological process which reacts fastest in a way that is visible in both RNA and protein expression.

Immediate early Sox9 expression is involved in ribosomal protein expression

To determine which prominent pathways link to the Sox9-dependent differential transcriptome and proteome at 2 hours in differentiation, we performed pathway analyses. Two independent Pathway analyses revealed that “Cytoplasmic Ribosomal Proteins” and “Ribosome” pathways were in the top three of identified enriched pathways (Figure 4). This strong overrepresentation of the “Cytoplasmic Ribosomal Proteins” and “Ribosome” pathways was not obvious in the Sox9-dependent differential transcriptome and proteome at day 7 in differentiation (Supplementary Table 7). Further analysis revealed the differential expression of 29 ribosomal protein encoding genes from the large (60S) ribosomal subunit (Rpls) and 10 ribosomal proteins from the small (40S) ribosomal subunit (Rpss) in the Sox9 knockdown condition at 2 hours in ATDC5 chondrogenic differentiation (Figure 5A and Supplementary Table 2). In addition, the 2 hours proteomics datasets demonstrated the differential expression of 5 ribosomal Rpl and Rps proteins (Figure 5A and Supplementary Table 4). Notably, the 4 overlapping mRNAs and proteins (Rps30/Fau, Avan, Eefsec, Rpl38) that were upregulated in the Sox9 knockdown condition at 2 hours in ATDC5 chondrogenic differentiation (Figure 3E and Figure 5B, Supplementary Figure 4A) are all linked to protein translation and represent either ribosomal

protein subunits or factors with a known function in ribosome biogenesis. Additional factors involved in ribosome biogenesis, but only differentially expressed in either the 2 hours transcriptomics or proteomics datasets were SBDS, Nop10 and Brix1 (Figure 5B. Supplementary Tables 2 and 3). Where expression of Sox9 was significantly increased at two hours in ATDC5 differentiation, expression of Rpl38, Rps30/Fau, Nop10 and SBDS was significantly decreased compared to t0 (Supplementary Figure 4C). Since ribosomes do not only consist of proteins, but depend on structural and catalytically active ribosomal RNAs (rRNAs), we investigated whether rRNA levels were affected by the Sox9 knockdown at 2 hours in differentiation in ATDC5. Expression of 18S rRNA, 28S rRNA and 5.8S rRNA was not significantly different between the conditions (Figure 5C) (see Supplemental Figure 4B for confirmation with independent Sox9 siRNA). Together, these data indicate that the Sox9 expression during early ATDC5 chondrogenic differentiation is involved in expression of ribosomal proteins and proteins involved in ribosome biogenesis.

Early Sox9 expression regulates protein translation capacity and ribosome translation modus

Since we identified the differential expression of ribosomal protein subunits and ribosome biogenesis factors, combined with unaltered rRNA expression levels, we hypothesized that ribosomes of early Sox9 knockdown ATDC5 cells are functionally distinct. To address this, we measured total translational capacity, performed polysome fractionation and evaluated ribosome translation modus in Sox9 knockdown and control ATDC5 cells. Following the knockdown of immediate early Sox9 expression a reduction of the total protein translational capacity was observed at 2 hours in chondrogenic differentiation (Figure 6A). The abrogation of early Sox9 expression also caused a reduction of total protein translational capacity at day 7 in differentiation (while Sox9 levels normalized at 7 days following the early knockdown (Figure 2B)). This impact on translation capacity was lost at day 14 in differentiation (Figure 6A). In contrast, late knockdown of Sox9 expression did not affect ATDC5 translational capacity at 7 days in chondrogenic differentiation. This is consistent with

transcriptome and proteome data. To assess if Sox9 knock-down had a specific effect on polysomal distribution of ribosomes, we performed sucrose density gradient separation of ribosomal subunits. Knockdown of the immediate early Sox9 expression resulted in an overall lower abundance of ribosomal subunits, which is in agreement with reduced translational activity (Figure 6B). In addition to total ribosome translation capacity (Figure 6A), the modus of translation is also subject to regulation. Thus, we evaluated the activity of IRES (internal ribosome entry site)- over cap-mediated protein translation using well-characterized bicistronic reporter constructs (CrPv IGR, HCV and P53 IRES) (44-46). We observed a 1.5-fold induction of the ITAF (IRES trans-acting factor) independent CrPv IGR IRES activity and 5-fold down regulation of both the HCV and P53 IRES activity in Sox9 knockdown ATDC5 cells compared to controls (Figure 6C, and Supplementary Figure 5). We next investigated whether overexpression of Sox9 levels during early ATDC5 differentiation may have a reciprocal effect on the translation capacity as opposed to the Sox9 knockdown conditions. Overexpression of Sox9 was confirmed (Figure 7A) and the mRNA expression of the Sox9 transcriptional target Col2a1 was significantly induced by Sox9 overexpression (Figure 7A). The overexpression of Sox9 resulted in a significant increase in translational capacity at 2 hours in ATDC5 differentiation (Figure 7B). This increase in translational capacity in the Sox9 overexpression condition was not accompanied by an increase in expression of rRNAs (Figure 7C). Contrary to the knockdown of Sox9 (Figure 5B), expression of ribosomal protein subunits Rpl38 and Rps30/Fau was significantly downregulated when Sox9 was overexpressed (Figure 7D). This was also the case for ribosome biogenesis factors Nop10 and SBDS (Figure 7D).

Taken together, knockdown of early Sox9 expression during ATDC5 chondrogenic differentiation reduced protein translational activity over a seven-day time period, which was reflected by a general reduction of A₂₆₀ signal in a polysome fractionation experiment at 2 hours in differentiation. This was associated with a differential effect on ribosome translation modus during the first day of

430 differentiation. Sox9 overexpression during early ATDC5 differentiation was able to induce reciprocal
431 effects of the Sox9 knockdown on total protein translation.

Discussion

Early chondrogenic lineage commitment during mesenchymal condensation is driven by Sox9 (15, 47, 48). Following lineage commitment, Sox9 is a key regulator of cartilage ECM synthesis, by driving expression of key ECM molecules such as Acan, Col2a1 and others (15, 19-26). Sox9 also safeguards maintenance of articular cartilage homeostasis by influencing chondrocyte Nkx3-2 levels, a transcriptional repressor of chondrocyte hypertrophy (49, 50). This dual action of Sox9 is recapitulated in *in vitro* models of chondrogenic differentiation, as we have previously reported on bi-phasic expression dynamics of Sox9 in ATDC5 and bone marrow derived stem cells (BMSC) chondrogenic differentiation (30, 31). In this earlier work we demonstrated that early (hours) transient induction of Sox9 expression driven by NFκB/p65 or Egr1 in ATDC5 chondrogenic differentiation is a prerequisite for late-stage (days) expression of cartilage ECM genes. As a key transcription factor for cartilage, the vast majority of investigations on the downstream functions of Sox9 have mainly focussed on its role in the transcriptional regulation of cartilage ECM genes (15, 19-26). In addition, a function in epigenetic reprogramming has been suggested for early Sox9 (31), as well as a role for Sox9 in activating super-enhancers in chondrocytic cells (51). However, its downstream cell biological consequences during early chondrogenic differentiation are incompletely understood. The present study demonstrates that Sox9 expression during the very early phase of ATDC5 chondrogenic differentiation regulates the expression of ribosomal protein subunits, as well as proteins that are involved in ribosome biogenesis that together modulate ribosome activity and translation modulus. These data, for the first time, connect the Sox9 transcription factor to regulation of protein translation during chondrogenic differentiation.

Ribosomopathies are severe genetic diseases caused by mutations in genes involved in ribosome biogenesis and -function and are, amongst others, associated with developmentally-related skeletal

malformations, caused by impairment of chondrogenic development of the growth plates (52, 53). This indicates that chondrogenic differentiation is particularly susceptible to disturbances in ribosome protein translation activity. Indeed, during chondrogenesis, a large amount of cartilage ECM is produced by the developing growth plate and disturbances in ribosome activity are likely to impair ECM synthesis, with consequences for the development of skeletal elements. It should however be noted that the link between Sox9 and chondrocyte translation activity in the current work was particularly present during early rather than late differentiation. This is highlighted by the deregulated expression of ribosomal subunits following Sox9 knockdown in early ATDC5 chondrogenic differentiation (Figure 4 and 5). In addition, the knockdown of Sox9 specifically impacted total protein translation throughout differentiation upon early knockdown, while not having an effect on protein translation when knocked-down during later in chondrogenic differentiation (Figure 6). The link between early Sox9 and chondrocyte protein translation suggests that protein translation is likely to be paced through Sox9 during early chondrogenic differentiation. However, it remains to be determined how early Sox9 is specifically able to influence chondrocyte translational capacity. Our present data suggest that expression of ribosomal protein subunits, ribosome biogenesis factors and ancillary ribosomal factors (such as IRES trans-acting factors (ITAFs)) depends on Sox9 during early chondrogenic differentiation, with downstream consequences for translation in the later differentiation program. Since we found these ribosomal genes and proteins differentially expressed after Sox9 knockdown, we studied the supplementary data of previously published Sox9 ChIP-seq and Sox9^{-/-} mouse studies (48, 51). In supplementary data of a Sox9 ChIP-seq study we found 24 Rps and Rpl genes that were enriched in Sox9 occupancy and 14 with Sox6 occupancy of which 10 overlapped (51). Notably, this included Rpl38, which we found to be differentially expressed at the mRNA and protein level in our present Sox9 knockdown condition.

479 Aside from ribosome core components, we identified Sox9-dependent differential expression of
 480 several factors regulating the mode of protein translation. The rate-limiting step of cap-mediated
 481 translation is eukaryotic initiation factor 4 (54). Interestingly, EIF4BP2 was downregulated at the
 482 protein level at 2 hours of differentiation in Sox9 knockdown cells. EIF4 binding proteins were shown
 483 to regulate cell proliferation, but not cell size (55). Unexpectedly, we found strong differences in IRES
 484 activity upon early Sox9 knockdown after 24 hours of differentiation. Of note, the CrPv IGR IRES (a
 485 type IV IRES (56)) does not require ITAFs and is able to recruit the ribosome directly for translation
 486 (57). The activity of this IRES was increased and might be regulated by specific Rps/Rpls that
 487 transiently interact with the core ribosome components. The HCV (a type III IRES) and P53 IRES do
 488 require additional ITAF co-factors (58). Based on the increased expression of the ITAF Rpl38 (59), it
 489 is tempting to speculate that other ITAFs that facilitate HCV/P53 IRES translation are down regulated
 490 and may contribute to alternative use of ribosome translation modus. Rpl10a, Rpl11, Rpl38 and Pdc4
 491 were shown to regulate IRES-mediated translation (58). Rpl10a is known to activate the *IGF2*, *APP*,
 492 *Chmp2A* and *Bcl-2* IRESs. Gain- and loss-of-function studies in *Drosophila* showed that *Rpl10a*
 493 regulates insulin signaling (60). Moreover, *Rpl10a* was found to be preferentially translated by a sub
 494 pool of ribosomes in embryonic stem cells that required ribosome-associated Rpl10a (61). Insulin and
 495 insulin-like growth factor I (IGF1) signaling are crucial for ATDC5 differentiation (32). Rpl11 induced
 496 the *BAG1*, *CSDE1* and *LamB1* IRESs, while *Rpl38* activated a Hox gene IRES (59, 62). Upregulation
 497 of *Rpl11* led to stabilization of P53 and reduced proliferation of breast cancer cell-lines (63). In
 498 contrast, we found a reduction in *P53* IRES activity. Of note, P53 and ribosome biogenesis were
 499 recently coupled through SBDS (Ribosome Maturation Factor)(63). In our dataset, SBDS was down
 500 regulated at the protein level at 2 hours in differentiation in Sox9 siRNA treated cells, which matches
 501 the observed reduction in ribosomes and/or ribosome activity. Pdc4 activated or inhibited the P53,
 502 INR, IGF1R, Bcl-XL and XIAP IRESs (58). The IGF1R IRES might again be relevant for the ATDC5
 503 differentiation model. Finally, Rpl38 was the only ITAF that was found to be upregulated at both the

504 mRNA and protein level. It was found to control HOX gene translation during murine embryonic
505 development (59) and knockout led to ectopic mineralization in certain soft tissues (64).

506 We identified multiple connections between immediate early Sox9 expression during ATDC5
507 chondrogenic differentiation and downstream consequences for expression of ribosomal protein
508 subunits, ribosome biogenesis factors and ITAFs. The connection between Sox9 expression and protein
509 translation appears to be centered in early chondrogenic differentiation, with consequences for protein
510 translation in later stage of chondrogenic differentiation. This suggests a role for early Sox9 in the
511 priming of progenitor cells in the chondrogenic differentiation program for cartilaginous ECM
512 production later in differentiation. This provides a new level of understanding how Sox9 controls the
513 fate of chondrogenic differentiation at the level of protein synthesis. In this respect it is tempting to
514 speculate on the classification of campomelic dysplasia (OMIM #114290) (65), as links between Sox9
515 and genes involved in ribosomopathies (52, 66) were identified in the present work (SBDS, Rpl11,
516 Rps26). In conclusion, we collected essential new data on the regulation by Sox9 during early
517 chondrogenic differentiation, uncovering an unanticipated role of Sox9 in ribosome biogenesis and
518 protein translational capacity.

519 **Acknowledgements**

520 This work was financially supported by the Dutch Arthritis Association (grant LLP14) and by the
521 Dutch Province of Limburg through the “LINK” program and by the MUMC institutional grant for
522 clinical collaborative research. The funders had no role in study design, data collection, and analysis,
523 decision to publish, or preparation of the manuscript.

524

525 **Contribution to the Field Statement**

526 In our previous research, we demonstrated that chondrogenic differentiation of progenitor cells is
527 driven by a sharply defined bi-phasic expression of Sox9: an immediate early and a late phase
528 expression. The late phase expression of Sox9 is associated with cartilage extracellular matrix
529 formation, while the function of the early Sox9 induction itself remained elusive. In this study we
530 aimed to determine what biological processes are driven by Sox9 during the early phase of
531 chondrogenic differentiation. We identified an essential new function for Sox9 during early
532 chondrogenic differentiation. A role for Sox9 in regulation of ribosome amount, activity and
533 composition was found and may be crucial in preparation for the demanding proliferative phase and
534 subsequent cartilage extracellular matrix-production of chondroprogenitors in the growth plate in vivo.

535

536 **Conflict of interest**

537 MMJ Caron and TJM Welting are inventor on patents WO2017178251 and WO2017178253 (licensed
538 to Chondropeptix). LW van Rhijn and TJM Welting have shares in Chondropeptix and are CDO and
539 CSO of Chondropeptix. All other authors have no competing interests to declare.

540 Funding

541 This work was financially supported by the Dutch Arthritis Association (grant LLP14) and by the
542 Dutch Province of Limburg through the “LINK” program and by the MUMC institutional grant for
543 clinical collaborative research. The funders had no role in study design, data collection, and analysis,
544 decision to publish, or preparation of the manuscript.

545

546 Data Availability Statement

547 RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI
548 (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-10333. Proteomics data can be found
549 in the ProteomeXchange Consortium via the PRIDE (37) partner repository with the dataset identifier
550 PXD024715. All other data used and/or analyzed during the current study are available from the
551 corresponding author on reasonable request.

552

553 Email addresses of all authors:

554 marjolein.caron@maastrichtuniversity.nl

555 m.eveque@maastrichtuniversity.nl

556 b.housmans@maastrichtuniversity.nl

557 kasper.derks@mumc.nl

558 a.cremers@maastrichtuniversity.nl

559 b.cilleropastor@maastrichtuniversity.nl

560 r.heeren@maastrichtuniversity.nl

561 m.j.peffers@liverpool.ac.uk

562 l.van.rhijn@mumc.nl

563 g.vandenakker@maastrichtuniversity.nl

564 t.welting@maastrichtuniversity.nl

References

1. H. M. Kronenberg: Developmental regulation of the growth plate. *Nature*, 423(6937), 332-6 (2003)
2. V. Lefebvre and P. Smits: Transcriptional control of chondrocyte fate and differentiation. *Birth Defects Res C Embryo Today*, 75(3), 200-12 (2005) doi:10.1002/bdrc.20048
3. E. J. Mackie, Y. A. Ahmed, L. Tatarczuch, K. S. Chen and M. Mirams: Endochondral ossification: how cartilage is converted into bone in the developing skeleton. *Int J Biochem Cell Biol*, 40(1), 46-62 (2008)
4. V. Abad, J. L. Meyers, M. Weise, R. I. Gafni, K. M. Barnes, O. Nilsson, J. D. Bacher and J. Baron: The role of the resting zone in growth plate chondrogenesis. *Endocrinology*, 143(5), 1851-7 (2002) doi:10.1210/endo.143.5.8776
5. C. Karlsson and A. Lindahl: Articular cartilage stem cell signalling. *Arthritis research & therapy*, 11(4), 121 (2009) doi:10.1186/ar2753
6. H. Nakahara, S. P. Bruder, V. M. Goldberg and A. I. Caplan: In vivo osteochondrogenic potential of cultured cells derived from the periosteum. *Clin Orthop Relat Res*(259), 223-32 (1990)
7. P. J. Emans, M. M. J. Caron, L. W. van Rhijn, V. P. Shastri and T. J. M. Welting: Cartilage Tissue Engineering; Lessons Learned From Periosteum. *Tissue Science & Engineering*, S2:002 (2011) doi:doi:10.4172/2157-7552.S2-002
8. F. P. Barry and J. M. Murphy: Mesenchymal stem cells: clinical applications and biological characterization. *The international journal of biochemistry & cell biology*, 36(4), 568-84 (2004) doi:10.1016/j.biocel.2003.11.001
9. M. M. French, S. Rose, J. Canseco and K. A. Athanasiou: Chondrogenic differentiation of adult dermal fibroblasts. *Ann Biomed Eng*, 32(1), 50-6 (2004) doi:10.1023/b:abme.00000007790.65773.e0
10. S. P. Medvedev, E. V. Grigor'eva, A. I. Shevchenko, A. A. Malakhova, E. V. Dementyeva, A. A. Shilov, E. A. Pokushalov, A. M. Zaidman, M. A. Aleksandrova, E. Y. Plotnikov, G. T. Sukhikh and S. M. Zakian: Human induced pluripotent stem cells derived from fetal neural stem cells successfully undergo directed differentiation into cartilage. *Stem cells and development*, 20(6), 1099-112 (2011) doi:10.1089/scd.2010.0249
11. B. de Crombrughe, V. Lefebvre and K. Nakashima: Regulatory mechanisms in the pathways of cartilage and bone formation. *Curr Opin Cell Biol*, 13(6), 721-7 (2001)
12. H. Mankin, V. Mow and J. Buckwalter: Articular cartilage structure, composition, and function. AAOS, Rosemont (2000)
13. J. W. Foster, M. A. Dominguez-Steglich, S. Guioli, C. Kwok, P. A. Weller, M. Stevanovic, J. Weissenbach, S. Mansour, I. D. Young, P. N. Goodfellow and et al.: Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. *Nature*, 372(6506), 525-30 (1994) doi:10.1038/372525a0
14. T. Wagner, J. Wirth, J. Meyer, B. Zabel, M. Held, J. Zimmer, J. Pasantès, F. D. Bricarelli, J. Keutel, E. Hustert, U. Wolf, N. Tommerup, W. Schempp and G. Scherer: Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. *Cell*, 79(6), 1111-20 (1994)
15. H. Akiyama, M. C. Chaboissier, J. F. Martin, A. Schedl and B. de Crombrughe: The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation

- 607 pathway and is required for expression of Sox5 and Sox6. *Genes Dev*, 16(21), 2813-28 (2002)
 608 doi:10.1101/gad.1017802
- 609 16. A. Argentaro, H. Sim, S. Kelly, S. Preiss, A. Clayton, D. A. Jans and V. R. Harley: A SOX9
 610 defect of calmodulin-dependent nuclear import in campomelic dysplasia/autosomal sex reversal. *The*
 611 *Journal of biological chemistry*, 278(36), 33839-47 (2003) doi:10.1074/jbc.M302078200
- 612 17. D. R. Haudenschild, J. Chen, N. Pang, M. K. Lotz and D. D. D'Lima: Rho kinase-dependent
 613 activation of SOX9 in chondrocytes. *Arthritis and rheumatism*, 62(1), 191-200 (2010)
 614 doi:10.1002/art.25051
- 615 18. S. Mertin, S. G. McDowall and V. R. Harley: The DNA-binding specificity of SOX9 and other
 616 SOX proteins. *Nucleic acids research*, 27(5), 1359-64 (1999)
- 617 19. Y. Han and V. Lefebvre: L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage
 618 by securing binding of Sox9 to a far-upstream enhancer. *Mol Cell Biol*, 28(16), 4999-5013 (2008)
 619 doi:10.1128/MCB.00695-08
- 620 20. V. Lefebvre, R. R. Behringer and B. de Crombrughe: L-Sox5, Sox6 and Sox9 control essential
 621 steps of the chondrocyte differentiation pathway. *Osteoarthritis Cartilage*, 9 Suppl A, S69-75 (2001)
- 622 21. V. Lefebvre, W. Huang, V. R. Harley, P. N. Goodfellow and B. de Crombrughe: SOX9 is a
 623 potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. *Mol Cell*
 624 *Biol*, 17(4), 2336-46 (1997)
- 625 22. V. Lefebvre, P. Li and B. de Crombrughe: A new long form of Sox5 (L-Sox5), Sox6 and Sox9
 626 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. *EMBO J*,
 627 17(19), 5718-33 (1998) doi:10.1093/emboj/17.19.5718
- 628 23. M. A. Genzer and L. C. Bridgewater: A Col9a1 enhancer element activated by two
 629 interdependent SOX9 dimers. *Nucleic acids research*, 35(4), 1178-86 (2007) doi:10.1093/nar/gkm014
- 630 24. E. Jenkins, J. B. Moss, J. M. Pace and L. C. Bridgewater: The new collagen gene COL27A1
 631 contains SOX9-responsive enhancer elements. *Matrix biology : journal of the International Society for*
 632 *Matrix Biology*, 24(3), 177-84 (2005) doi:10.1016/j.matbio.2005.02.004
- 633 25. C. D. Oh, S. N. Maity, J. F. Lu, J. Zhang, S. Liang, F. Coustry, B. de Crombrughe and H.
 634 Yasuda: Identification of SOX9 interaction sites in the genome of chondrocytes. *PLoS One*, 5(4),
 635 e10113 (2010) doi:10.1371/journal.pone.0010113
- 636 26. O. Rentsendorj, A. Nagy, I. Sinko, A. Daraba, E. Barta and I. Kiss: Highly conserved proximal
 637 promoter element harbouring paired Sox9-binding sites contributes to the tissue- and developmental
 638 stage-specific activity of the matrilin-1 gene. *The Biochemical journal*, 389(Pt 3), 705-16 (2005)
 639 doi:10.1042/BJ20050214
- 640 27. T. Furumatsu, M. Tsuda, N. Taniguchi, Y. Tajima and H. Asahara: Smad3 induces
 641 chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. *The*
 642 *Journal of biological chemistry*, 280(9), 8343-50 (2005) doi:10.1074/jbc.M413913200
- 643 28. W. Wang, D. Rigueur and K. M. Lyons: TGFbeta signaling in cartilage development and
 644 maintenance. *Birth Defects Res C Embryo Today*, 102(1), 37-51 (2014) doi:10.1002/bdrc.21058
- 645 29. B. S. Yoon and K. M. Lyons: Multiple functions of BMPs in chondrogenesis. *J Cell Biochem*,
 646 93(1), 93-103 (2004) doi:10.1002/jcb.20211

30. M. M. Caron, P. J. Emans, D. A. Surtel, A. Cremers, J. W. Voncken, T. J. Welting and L. W. van Rhijn: Activation of NF-kappaB/p65 Facilitates Early Chondrogenic Differentiation during Endochondral Ossification. *PloS one*, 7(3), e33467 (2012) doi:10.1371/journal.pone.0033467
31. F. Spaapen, G. G. van den Akker, M. M. Caron, P. Prickaerts, C. Rofel, V. E. Dahlmans, D. A. Surtel, Y. Paulis, F. Schweizer, T. J. Welting, L. M. Eijssen and J. W. Voncken: The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis. *PLoS One*, 8(3), e58083 (2013) doi:10.1371/journal.pone.0058083
32. T. Atsumi, Y. Miwa, K. Kimata and Y. Ikawa: A chondrogenic cell line derived from a differentiating culture of AT805 teratocarcinoma cells. *Cell Differ Dev*, 30(2), 109-16 (1990)
33. T. J. Welting, M. M. Caron, P. J. Emans, M. P. Janssen, K. Sanen, M. M. Coolen, L. Voss, D. A. Surtel, A. Cremers, J. W. Voncken and L. W. van Rhijn: Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic differentiation during endochondral ossification. *Eur Cell Mater*, 22, 420-36; discussion 436-7 (2011)
34. M. D. Robinson, D. J. McCarthy and G. K. Smyth: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, 26(1), 139-40 (2010) doi:10.1093/bioinformatics/btp616
35. D. J. McCarthy, Y. Chen and G. K. Smyth: Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res*, 40(10), 4288-97 (2012) doi:10.1093/nar/gks042
36. E. Y. Chen, C. M. Tan, Y. Kou, Q. Duan, Z. Wang, G. V. Meirelles, N. R. Clark and A. Ma'ayan: Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics*, 14, 128 (2013) doi:10.1186/1471-2105-14-128
37. Y. Perez-Riverol, A. Csordas, J. Bai, M. Bernal-Llinares, S. Hewapathirana, D. J. Kundu, A. Inuganti, J. Griss, G. Mayer, M. Eisenacher, E. Perez, J. Uszkoreit, J. Pfeuffer, T. Sachsenberg, S. Yilmaz, S. Tiwary, J. Cox, E. Audain, M. Walzer, A. F. Jarnuczak, T. Ternent, A. Brazma and J. A. Vizcaino: The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res*, 47(D1), D442-D450 (2019) doi:10.1093/nar/gky1106
38. R. W. Farndale, C. A. Sayers and A. J. Barrett: A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. *Connective tissue research*, 9(4), 247-8 (1982)
39. C. A. Goodman and T. A. Hornberger: Measuring protein synthesis with SUnSET: a valid alternative to traditional techniques? *Exerc Sport Sci Rev*, 41(2), 107-15 (2013) doi:10.1097/JES.0b013e3182798a95
40. C. J. Henrich: A Microplate-Based Nonradioactive Protein Synthesis Assay: Application to TRAIL Sensitization by Protein Synthesis Inhibitors. *PLoS One*, 11(10), e0165192 (2016) doi:10.1371/journal.pone.0165192
41. T. A. McCaffrey, L. A. Agarwal and B. B. Weksler: A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro. *In Vitro Cell Dev Biol*, 24(3), 247-52 (1988) doi:10.1007/bf02623555
42. A. C. Panda, J. L. Martindale and M. Gorospe: Polysome Fractionation to Analyze mRNA Distribution Profiles. *Bio-protocol*, 7(3), e2126 (2017) doi:10.21769/BioProtoc.2126
43. C. Vogel and E. M. Marcotte: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. *Nat Rev Genet*, 13(4), 227-32 (2012) doi:10.1038/nrg3185

- 689 44. N. Deniz, E. M. Lenarcic, D. M. Landry and S. R. Thompson: Translation initiation factors are
690 not required for Dicistroviridae IRES function in vivo. *Rna*, 15(5), 932-46 (2009)
691 doi:10.1261/rna.1315109
- 692 45. A. J. Collier, S. Tang and R. M. Elliott: Translation efficiencies of the 5' untranslated region
693 from representatives of the six major genotypes of hepatitis C virus using a novel bicistronic reporter
694 assay system. *J Gen Virol*, 79 (Pt 10), 2359-66 (1998) doi:10.1099/0022-1317-79-10-2359
- 695 46. P. S. Ray, R. Grover and S. Das: Two internal ribosome entry sites mediate the translation of
696 p53 isoforms. *EMBO Rep*, 7(4), 404-10 (2006) doi:10.1038/sj.embor.7400623
- 697 47. V. Lefebvre, M. Angelozzi and A. Haseeb: SOX9 in cartilage development and disease. *Curr*
698 *Opin Cell Biol*, 61, 39-47 (2019) doi:10.1016/j.ceb.2019.07.008
- 699 48. C. F. Liu, M. Angelozzi, A. Haseeb and V. Lefebvre: SOX9 is dispensable for the initiation of
700 epigenetic remodeling and the activation of marker genes at the onset of chondrogenesis. *Development*,
701 145(14) (2018) doi:10.1242/dev.164459
- 702 49. M. M. Caron, P. J. Emans, D. A. Surtel, P. M. van der Kraan, L. W. van Rhijn and T. J. Welting:
703 BAPX-1/NKX-3.2 acts as a chondrocyte hypertrophy molecular switch in osteoarthritis. *Arthritis*
704 *Rheumatol*, 67(11), 2944-56 (2015) doi:10.1002/art.39293
- 705 50. S. Yamashita, M. Andoh, H. Ueno-Kudoh, T. Sato, S. Miyaki and H. Asahara: Sox9 directly
706 promotes Bapx1 gene expression to repress Runx2 in chondrocytes. *Exp Cell Res*, 315(13), 2231-40
707 (2009) doi:10.1016/j.yexcr.2009.03.008
- 708 51. C. F. Liu and V. Lefebvre: The transcription factors SOX9 and SOX5/SOX6 cooperate
709 genome-wide through super-enhancers to drive chondrogenesis. *Nucleic Acids Res*, 43(17), 8183-203
710 (2015) doi:10.1093/nar/gkv688
- 711 52. P. A. Trainor and A. E. Merrill: Ribosome biogenesis in skeletal development and the
712 pathogenesis of skeletal disorders. *Biochim Biophys Acta*, 1842(6), 769-78 (2014)
713 doi:10.1016/j.bbadis.2013.11.010
- 714 53. G. Venturi and L. Montanaro: How Altered Ribosome Production Can Cause or Contribute to
715 Human Disease: The Spectrum of Ribosomopathies. *Cells*, 9(10) (2020) doi:10.3390/cells9102300
- 716 54. Y. V. Svitkin, B. Herdy, M. Costa-Mattioli, A. C. Gingras, B. Raught and N. Sonenberg:
717 Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and
718 internal ribosomal entry site-mediated translation. *Mol Cell Biol*, 25(23), 10556-65 (2005)
719 doi:10.1128/MCB.25.23.10556-10565.2005
- 720 55. R. J. Dowling, I. Topisirovic, T. Alain, M. Bidinosti, B. D. Fonseca, E. Petroulakis, X. Wang,
721 O. Larsson, A. Selvaraj, Y. Liu, S. C. Kozma, G. Thomas and N. Sonenberg: mTORC1-mediated cell
722 proliferation, but not cell growth, controlled by the 4E-BPs. *Science*, 328(5982), 1172-6 (2010)
723 doi:10.1126/science.1187532
- 724 56. A. G. Johnson, R. Grosely, A. N. Petrov and J. D. Puglisi: Dynamics of IRES-mediated
725 translation. *Philos Trans R Soc Lond B Biol Sci*, 372(1716) (2017) doi:10.1098/rstb.2016.0177
- 726 57. E. Jan and P. Sarnow: Factorless ribosome assembly on the internal ribosome entry site of
727 cricket paralysis virus. *J Mol Biol*, 324(5), 889-902 (2002) doi:10.1016/s0022-2836(02)01099-9
- 728 58. A. C. Godet, F. David, F. Hantelys, F. Tatin, E. Lacazette, B. Garmy-Susini and A. C. Prats:
729 IRES Trans-Acting Factors, Key Actors of the Stress Response. *Int J Mol Sci*, 20(4) (2019)
730 doi:10.3390/ijms20040924

59. S. Xue, S. Tian, K. Fujii, W. Kladwang, R. Das and M. Barna: RNA regulons in Hox 5' UTRs confer ribosome specificity to gene regulation. *Nature*, 517(7532), 33-38 (2015) doi:10.1038/nature14010
60. N. Chaichanit, M. Wonglapsuwan and W. Chotigeat: Ribosomal protein L10A and signaling pathway. *Gene*, 674, 170-177 (2018) doi:10.1016/j.gene.2018.06.081
61. Z. Shi, K. Fujii, K. M. Kovary, N. R. Genuth, H. L. Röst, M. N. Teruel and M. Barna: Heterogeneous Ribosomes Preferentially Translate Distinct Subpools of mRNAs Genome-wide. *Mol Cell*, 67(1), 71-83.e7 (2017) doi:10.1016/j.molcel.2017.05.021
62. R. Horos, H. Ijspeert, D. Pospisilova, R. Sendtner, C. Andrieu-Soler, E. Taskesen, A. Nieradka, R. Cmejla, M. Sendtner, I. P. Touw and M. von Lindern: Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts. *Blood*, 119(1), 262-72 (2012) doi:10.1182/blood-2011-06-358200
63. D. Tong, J. Zhang, X. Wang, Q. Li, L. Y. Liu, J. Yang, B. Guo, L. Ni, L. Zhao and C. Huang: MeCP2 facilitates breast cancer growth via promoting ubiquitination-mediated P53 degradation by inhibiting RPL5/RPL11 transcription. *Oncogenesis*, 9(5), 56 (2020) doi:10.1038/s41389-020-0239-7
64. K. Noben-Trauth and J. R. Latoche: Ectopic mineralization in the middle ear and chronic otitis media with effusion caused by RPL38 deficiency in the Tail-short (Ts) mouse. *The Journal of biological chemistry*, 286(4), 3079-3093 (2011) doi:10.1074/jbc.M110.184598
65. G. R. Mortier, D. H. Cohn, V. Cormier-Daire, C. Hall, D. Krakow, S. Mundlos, G. Nishimura, S. Robertson, L. Sangiorgi, R. Savarirayan, D. Sillence, A. Superti-Furga, S. Unger and M. L. Warman: Nosology and classification of genetic skeletal disorders: 2019 revision. *Am J Med Genet A*, 179(12), 2393-2419 (2019) doi:10.1002/ajmg.a.61366
66. H. Nakhoul, J. Ke, X. Zhou, W. Liao, S. X. Zeng and H. Lu: Ribosomopathies: mechanisms of disease. *Clin Med Insights Blood Disord*, 7, 7-16 (2014) doi:10.4137/CMBD.S16952
67. H. Heberle, G. V. Meirelles, F. R. da Silva, G. P. Telles and R. Minghim: InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics*, 16, 169 (2015) doi:10.1186/s12859-015-0611-3
68. D. N. Slenter, M. Kutmon, K. Hanspers, A. Riutta, J. Windsor, N. Nunes, J. Melius, E. Cirillo, S. L. Coort, D. Digles, F. Ehrhart, P. Giesbertz, M. Kalafati, M. Martens, R. Miller, K. Nishida, L. Rieswijk, A. Waagmeester, L. M. T. Eijssen, C. T. Evelo, A. R. Pico and E. L. Willighagen: WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. *Nucleic Acids Res*, 46(D1), D661-D667 (2018) doi:10.1093/nar/gkx1064
69. M. Kutmon, M. P. van Iersel, A. Bohler, T. Kelder, N. Nunes, A. R. Pico and C. T. Evelo: PathVisio 3: an extendable pathway analysis toolbox. *PLoS Comput Biol*, 11(2), e1004085 (2015) doi:10.1371/journal.pcbi.1004085

Figure legends

Figure 1: Sox9 expression has a bi-phasic peak expression during chondrogenic differentiation of ATDC5 cells

A: Sox9 mRNA expression showed bi-phasic peak pattern during ATDC5 differentiation (h=hours, d=days) as measured by RT-qPCR (30, 31). Results were normalized to β -Actin mRNA expression and presented relative to t=0. **B:** Sox9 protein expression peak during early ATDC5 differentiation as measured by immunoblotting. α -Tubulin was used as loading control. Molecular weight markers (in kDa) are shown on the left and relative quantifications are depicted on top of immunoblot. **C:** In similar samples from (A), Col2a1 mRNA expression was measured during ATDC5 differentiation by RT-qPCR and showed an increase in expression from day 6 onwards. **D:** GAG content (by Alcian Blue staining and corrected for total protein expression) was determined during ATDC5 differentiation. Experiments were performed in triplicate, bars represent mean \pm SEM. ns= not significant, *=p<0.05, **=p<0.01, ***=p<0.0001.

Figure 2: Elucidating the function of early Sox9 expression by transcriptome and proteome analyses

A: Schematic representation of experimental set-up for Sox9 knockdown experiment. Specific Sox9 RNAi (100 nM) or scrambled control RNAi (100 nM) were transiently transfected “early” at t=-1d or “late” t=6d. ATDC5 cells were differentiated from day 0 onwards and harvested for transcriptome and proteome analysis at t=0, 2h, 5d, 7d, 14d. **B:** Sox9 mRNA expression during ATDC5 differentiation in Control and Sox9 RNAi conditions (h=hours, d=days) as measured by RT-qPCR. Results were normalized to β -Actin RNA expression and presented relative to t=0. Bars represent mean \pm SEM. ns=

not significant, $\ast=p<0.05$, $\ast\ast=p<0.01$, $p=<0.0001$. **C:** Sox9 protein expression at $t=2h$ (for “early knockdown condition) and $t=7d$ (for “late” knockdown conditions) time point in Control and Sox9 RNAi conditions as measured by immunoblotting. α -Tubulin was used as loading control. Molecular weight markers (in kd) are shown on the left. **D:** Col2a1 mRNA expression in similar samples from (B). **E:** Col10a1 mRNA expression in similar samples from (B). **F:** Schematic representation of time points and comparisons for transcriptomics and proteomics analysis.

Figure 3: Changes in transcriptome and proteome after Sox9 knockdown

A: Venn diagram (67) showing the numbers of genes whose expression was significantly upregulated upon Sox9 knockdown at 2 hours versus 7 day condition. **B:** Venn diagram showing the numbers of genes whose expression was significantly downregulated upon Sox9 knockdown at 2 hours versus 7 day condition. **C:** Venn diagram showing the numbers of proteins whose expression was significantly upregulated upon Sox9 knockdown at 2 hours versus 7 day condition. **D:** Venn diagram showing the numbers of proteins whose expression was significantly downregulated upon Sox9 knockdown at 2 hours versus 7 day condition. **E:** Venn diagram showing the upregulated genes versus proteins at 2 hours in differentiation. **F:** Venn diagram showing the downregulated genes versus proteins at 2 hours in differentiation.

Figure 4: Early Sox9 expression is involved in ribosomal pathways

Top 3 identified enriched pathways from WikiPathway 2019 and KEGG2019 pathway analysis in control RNAi compared to Sox9 RNAi at 2 hours condition in ATDC5 differentiation for transcriptome and proteome data sets.

Figure 5: Early Sox9 regulates ribosomal protein expression

A: Schematic representation of significantly differentially expressed ribosomal proteins from transcriptome and proteome datasets based on Wikipathways (68): WP163 using PathVisio 3 (69). **B:** Rpl38, Rps30/Fau, Nop10 and SBDS expression at 2 hours in ATDC5 differentiation in Control and Sox9 RNAi conditions as measured by RT-qPCR. Results were normalized to β -Actin RNA expression and presented relative to t=0. **C:** In similar samples from B; 18S rRNA, 28S rRNA and 5.8S rRNA expression. Bars represent mean \pm SEM. ns= not significant, *=p<0.05, **=p<0.01, ***=p<0.0001.

Figure 6: Knockdown of early Sox9 expression leads to a reduced translational capacity, lower amount of ribosomes and alters ribosome modus

A: Total protein translation measurements based on puromycin incorporation was normalized to total DNA content per well (Mean \pm SEM, n=6/group) at indicated time points. **B:** Polysome fractionation of control and Sox9 knock-down cells (Mean only, n=3/group) after 2 hours of differentiation. **C:** Ribosome modus was assessed for the CrPv IGR CCGG mutant IRES, the intact CrPv IGR IRES, the HCV IRES and the P53 IRES after 24 hours of differentiation. Bars represent mean \pm SEM. ns= not significant, *=p<0.05, **=p<0.01, p=<0.0001.

Figure 7: Overexpression of early Sox9 leads to an increased translational capacity

A: Sox9 mRNA expression at 2 hours in ATDC5 differentiation in Control and Sox9 overexpression (OE) conditions as measured by RT-qPCR. Results were normalized to β -Actin RNA expression and presented relative to t=0. **B:** Total protein translation measurements based on puromycin incorporation was normalized to total DNA content per well (Mean \pm SEM, n=6/group) at indicated time points. **C:**

836 In similar samples from A; 18S rRNA, 28S rRNA and 5.8S rRNA expression at 2 hours in ATDC5
837 differentiation in Control and Sox9 overexpression conditions. **D:** In similar samples from A; *Rpl38*,
838 *Rps30/Fau*, *Nop10* and SBDS expression at 2 hours in ATDC5 differentiation in Control and Sox9
839 overexpression conditions. Bars represent mean \pm SEM. ns= not significant, *=p<0.05, **=p<0.01,
840 p=<0.0001.